Tyenne Injection, Solution
Product Images NDC 65219-598

Product Visual Gallery

This gallery contains 67 technical images submitted to the FDA as part of the official labeling for Tyenne (NDC 65219-598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tocli-img-01.jpg (Tocil Img 01)

A line graph showing the percentage of patients achieving an ACR20 response over time (weeks 2 to 24). The graph compares three treatment groups: Placebo plus MTX, Tocilizumab 8 mg/kg plus MTX, and Tocilizumab 4 mg/kg plus MTX. The y-axis represents the percentage of ACR20 responders with standard error, and the x-axis shows visits by week.*

FDA Label Image

Tocli-img-02.jpg (Tocil Img 02)

A forest plot chart displaying risk difference with 95% confidence intervals for mortality across four studies comparing Tocilizumab plus standard of care (SOC) versus SOC alone. The chart includes study names, total sample sizes, number and percentage of deaths in each group, and a summary overall risk difference, showing favorability on a scale from -20.0 to 20.0.*

FDA Label Image

Tocli-img-03.jpg (Tocil Img 03)

Instructions for use panel for Tyenne (tocilizumab-aazg) injection, 162 mg/0.9 mL, for subcutaneous use only. The image includes a depiction of the single-dose autoinjector device and advises to read instructions carefully before use.*

FDA Label Image

Tocli-img-04.jpg (Tocil Img 04)

An instructional diagram of a TYENNE (Tocilizumab-aazg) injection pen showing labeled parts: Clear cap, Window, Medicine inside, and Body. The pen is designed for subcutaneous injection and contains 162 mg/0.9 mL solution.*

FDA Label Image

Tocli-img-05.jpg (Tocil Img 05)

An illustration diagram of a Tyenne injection device showing labeled parts including the Needle Cover, Window, Body, and Plunger Rod. The device is used for subcutaneous injection of Tocilizumab-aazg solution.*

FDA Label Image

Tocli-img-06.jpg (Tocil Img 06)

Instructional graphic showing 'Step 1' with the text 'Prepare for your injection,' indicating the initial step in an injection preparation process.*

FDA Label Image

Tocli-img-07.jpg (Tocil Img 07)

An instructional illustration showing a sharps disposal container labeled 'Sharps Disposal,' an alcohol pad packet, and a sterile cotton ball, labeled respectively, likely indicating items needed or used for injection safety or preparation.*

FDA Label Image

Tocli-img-08.jpg (Tocil Img 08)

Illustration of a carton box labeled as Figure B, featuring a magnified view of an expiration date area marked as EAP: YYYY-MM.*

FDA Label Image

Tocli-img-09.jpg (Tocil Img 09)

An instructional illustration showing a clock with the label '45 min' and a device or tray below it, likely indicating a 45-minute time duration related to the use or preparation of the product.*

FDA Label Image

Tocli-img-10.jpg (Tocil Img 10)

An instructional illustration labeled Figure D showing a hand holding an injection pen and another hand positioned below it, likely demonstrating how to administer a subcutaneous injection using the device.*

FDA Label Image

Tocli-img-11.jpg (Tocil Img 11)

An instructional image panel labeled "Step 2" showing a purple and orange arrow pointing right, with white text instructing to "Check your autoinjector." This appears to be part of a step-by-step guide for using a medication autoinjector device.*

FDA Label Image

Tocli-img-12.jpg (Tocil Img 12)

An instructional illustration labeled Figure E showing a close-up of a finger pressing down on the plunger of a prefilled syringe, demonstrating how to administer the injection. The syringe contains a solution intended for subcutaneous injection.*

FDA Label Image

Tocli-img-13.jpg (Tocil Img 13)

An illustration labeled as Figure F showing a close-up view of an injection pen with a magnified circle highlighting the location of the expiration date (formatted as EXP: YYYY-MM) on the device. The injection pen appears to be intended for administering a 162 mg/0.9 mL subcutaneous solution of Tocilizumab-aazg (brand name TYENNE) by Fresenius Kabi USA, LLC.*

FDA Label Image

Tocli-img-14.jpg (Tocil Img 14)

An instructional diagram showing the correct and incorrect appearances of particles in a solution-filled syringe. The 'Correct' illustration depicts a clear syringe without visible particles, while the 'Incorrect' shows a syringe containing small black particles inside the solution.*

FDA Label Image

Tocli-img-15.jpg (Tocil Img 15)

An instructional graphic labeled 'Step 3' instructing to 'Wash your hands.' The design features an orange arrow pointing to the right with white text and a purple background behind the main instruction text.*

FDA Label Image

Tocli-img-16.jpg (Tocil Img 16)

An instructional illustration labeled as Figure H shows a person washing their hands under a faucet with running water and soap bubbles visible, demonstrating proper hand hygiene.*

FDA Label Image

Tocli-img-17.jpg (Tocil Img 17)

Instructional graphic showing Step 4: Choose the injection site, with white text on a purple arrow pointing right and orange background on the left, guiding proper injection site selection.*

FDA Label Image

Tocli-img-18.jpg (Tocil Img 18)

Instructional diagram showing injection sites for TYENNE (Tocilizumab-aazg) subcutaneous injection. It illustrates areas on the human body where injections can be administered by self or caregiver (abdomen and thighs) and areas restricted for caregiver-only administration (back upper arms).*

FDA Label Image

Tocli-img-19.jpg (Tocil Img 19)

An instructional illustration panel labeled Step 5, showing the text "Clean the injection site" on a purple background with an orange arrow indicating the step number.*

FDA Label Image

Tocli-img-20.jpg (Tocil Img 20)

Illustration labeled 'Figure J' depicting a hand administering a subcutaneous injection into a person's thigh, demonstrating the proper injection technique for a medication such as TYENNE (tocilizumab-aazg) injection.*

FDA Label Image

Tocli-img-21.jpg (Tocil Img 21)

Instructional graphic showing Step 6 with the text 'Give your injection' on a purple background with an orange arrow pointing right. The image is part of a stepwise guide, likely related to administering an injection.*

FDA Label Image

Tocli-img-22.jpg (Tocil Img 22)

An instructional diagram showing the removal of an orange cap from a syringe or injection device by pulling it upward, indicated by a purple arrow. This image guides on preparing the TYENNE 162 mg/0.9 mL subcutaneous injection solution for administration.*

FDA Label Image

Tocli-img-23.jpg (Tocil Img 23)

An instructional illustration showing a hand holding a device vertically at a 90-degree angle to the skin, indicating the proper injection angle for a subcutaneous injection. This diagram is likely related to administering TYENNE (Tocilizumab-aazg) injection, solution, 162 mg/0.9 mL.*

FDA Label Image

Tocli-img-24.jpg (Tocil Img 24)

An instructional illustration showing a hand holding an injection device with an arrow indicating to press and click the start button, followed by the instruction to keep holding down the button. The diagram visually guides the user on how to properly administer a subcutaneous injection, likely for the product Tocilizumab-aazg 162 mg/0.9 mL.*

FDA Label Image

Tocli-img-25.jpg (Tocil Img 25)

An instructional diagram showing how to administer a subcutaneous injection with a TYENNE Tocilizumab-aazg 162 mg/0.9 mL device. The image indicates pressing until the second click, holding down for 10 seconds before completing the injection.*

FDA Label Image

Tocli-img-26.jpg (Tocil Img 26)

An instructional illustration showing a hand holding a syringe with an arrow pointing downward towards a vial or injection container. Beside it is a timer icon with the text 'WAIT 5 sec,' indicating a 5-second waiting period. The figure is labeled 'Figure O.'*

FDA Label Image

Tocli-img-27.jpg (Tocil Img 27)

An instructional illustration showing an eye and a syringe with a dashed line suggesting the syringe is to be used near the eye area. The syringe is partially filled with liquid and held vertically.*

FDA Label Image

Tocli-img-28.jpg (Tocil Img 28)

Instructional diagram step labeled 'Step 7' with text 'Remove and check the autoinjector'. It appears as part of a series of instructions related to the use of an injection device.*

FDA Label Image

Tocil-img-29.jpg (Tocil Img 29)

An instructional illustration showing a hand pulling off an orange cap from a syringe needle, suggesting a step in preparing a subcutaneous injection for administration.*

FDA Label Image

Tocli-img-30.jpg (Tocil Img 30)

An instructional illustration showing a hand holding a syringe vertically, highlighting the preparation or injection technique of a drug solution.*

FDA Label Image

Tocli-img-31.jpg (Tocil Img 31)

An instructional illustration showing a hand pinching the skin of a person's upper arm, indicating preparation for a subcutaneous injection using a prefilled syringe or similar device.*

FDA Label Image

Tocli-img-32.jpg (Tocil Img 32)

Illustration showing Step 8 in an autoinjector usage guide, instructing the user to throw away the autoinjector after use. The image features a purple arrow containing the guidance text with an orange section indicating the step number.*

FDA Label Image

Tocli-img-33.jpg (Tocil Img 33)

An instructional illustration showing a syringe being disposed of into a sharps disposal container labeled 'Sharps Disposal.' This diagram emphasizes safe handling and disposal of needles, as part of proper injection practices.*

FDA Label Image

Tocli-img-34.jpg (Tocil Img 34)

An instructional image labeled Step 9, advising to record the date of administration and injection site. The text is white on an orange and purple gradient background.*

FDA Label Image

Tocli-img-35.jpg (Tocil Img 35)

An instructional illustration showing a hand holding a syringe for subcutaneous injection. The image includes a label area titled 'Record date of administration and injection site,' with example text indicating 'Date of administration: 11/24/22' and 'Injection site: Left thigh.' The figure is labeled as Figure U.*

FDA Label Image

Tocli-img-36.jpg (Tocil Img 36)

Instructions for use panel for Tyenne (tocilizumab-aazg) 162 mg/0.9 mL injection. The panel indicates it is a single-dose prefilled syringe for subcutaneous use only, accompanied by an image of the prefilled syringe with the Tyenne label.*

FDA Label Image

Tocli-img-37.jpg (Tocil Img 37)

Instructional diagram showing front and back views of a TYENNE (tocilizumab-aazg) 162 mg/0.9 mL subcutaneous injection prefilled syringe before and after use. It highlights syringe parts including clear needle guard, needle cap, liquid-filled barrel, finger flange, plunger, expiration date, and extended needle guard spring after use.*

FDA Label Image

Tocli-img-38.jpg (Tocil Img 38)

An instructional banner image labeled 'Step 1 Prepare for your injection' with a purple background and an orange arrow pointing right. This image is part of a step-by-step guide preparing patients for an injection, likely for the medication TYENNE (Tocilizumab-aazg).*

FDA Label Image

Tocli-img-39.jpg (Tocil Img 39)

An instructional illustration showing components for subcutaneous injection with TYENNE prefilled syringe (tocilizumab-aazg). The diagram includes a sharps disposal container, an alcohol pad, a sterile cotton ball, and the TYENNE prefilled syringe with a needle cap labeled as Figure B.*

FDA Label Image

Tocli-img-40.jpg (Tocil Img 40)

An instructional illustration showing a hand removing a TYENNE injection solution box from a refrigerator. A close-up circle highlights a blue tab on the box being lifted upwards, indicating how to open the packaging properly.*

FDA Label Image

Tocli-img-41.jpg (Tocil Img 41)

An instructional figure labeled as Figure D showing a purple clock icon indicating 30 minutes. This image likely represents a time duration of 30 minutes in the context of the medication instructions.*

FDA Label Image

Tocli-img-42.jpg (Tocil Img 42)

An instructional diagram panel labeled 'Step 2 Check the syringe' with white text on a purple background and an orange arrow. It appears to be part of a multi-step injection or medication administration guide.*

FDA Label Image

Tocli-img-43.jpg (Tocil Img 43)

Illustration showing a hand removing or lifting a prefilled syringe labeled TYENNE from packaging. The syringe contains an orange plunger and is positioned within a molded plastic tray, demonstrating part of the drug administration or preparation process for subcutaneous injection.*

FDA Label Image

Tocli-img-44.jpg (Tocil Img 44)

Illustration of a TYENNE injection pen containing Tocilizumab-aazg, 162 mg/0.9 mL, labeled with spaces for lot number and expiration date. The image highlights the label area on the pen and placeholders for important identifying information.*

FDA Label Image

Tocli-img-45.jpg (Tocil Img 45)

An instructional diagram showing a close-up view of a TYENNE injection solution vial or syringe with a focus on the label area, indicated by an eye icon and dashed lines highlighting the product name Tyenne on the label.*

FDA Label Image

Tocli-img-46.jpg (Tocil Img 46)

An instructional illustration showing proper handling and administration technique for the Tyenne (tocilizumab-aazg) 162 mg/0.9 mL subcutaneous injection. Figures highlight correct syringe positioning and injection methods with visual indicators for proper and improper techniques.*

FDA Label Image

Tocli-img-47.jpg (Tocil Img 47)

An instructional image labeled 'Step 3' with the directive 'Wash your hands.' The background transitions from orange on the left to purple on the right, highlighting the handwashing instruction as part of a multi-step process.*

FDA Label Image

Tocli-img-48.jpg (Tocil Img 48)

An instructional graphic labeled 'Step 4' with the text 'Choose the injection site' on a purple background, accompanied by an orange arrow on the left. The style suggests it is part of a multi-step guide for administering a medication.*

FDA Label Image

Tocli-img-49.jpg (Tocil Img 49)

An instructional illustration showing injection sites for TYENNE (tocilizumab-aazg) 162 mg/0.9 mL subcutaneous injection. Figure L depicts front view sites for self or caregiver injection on the abdomen and thighs. Figure M shows back view sites for caregiver-only injection on the upper arms.*

FDA Label Image

Tocli-img-50.jpg (Tocil Img 50)

An instructional graphic showing Step 5 in a process, with the text 'Clean the injection site' displayed inside a purple box with an orange arrow containing the text 'Step 5' pointing to the instruction text.*

FDA Label Image

Tocli-img-51.jpg (Tocil Img 51)

An instructional graphic labeled Step 6 with the instruction to 'Give your injection' in white text on a purple background, accompanied by an orange arrow pointing right with the step number.*

FDA Label Image

Tocli-img-52.jpg (Tocil Img 52)

An instructional illustration showing hands preparing a syringe by removing the cap from a needle before injection. This is related to the administration of TYENNE (Tocilizumab-aazg) 162 mg/0.9 mL subcutaneous injection, highlighting the step of needle preparation for use.*

FDA Label Image

Tocli-img-53.jpg (Tocil Img 53)

An illustration showing a hand holding a subcutaneous injection device with a visible orange plunger, demonstrating how to hold the injection pen. The image is likely part of instructional material on administering TYENNE (tocilizumab-aazg) 162 mg/0.9 mL injection.*

FDA Label Image

Tocli-img-54.jpg (Tocil Img 54)

An instructional diagram showing a hand pinching the skin, likely demonstrating a subcutaneous injection technique. The diagram is labeled as Figure P.*

FDA Label Image

Tocli-img-55.jpg (Tocil Img 55)

An instructional illustration showing a hand holding a 162 mg/0.9 mL subcutaneous injection syringe at approximately a 45-degree angle to the skin of another hand, indicating the proper injection angle for the medication TYENNE (tocilizumab-aazg).*

FDA Label Image

Tocli-img-56.jpg (Tocil Img 56)

An instructional illustration showing a hand holding a syringe to administer an injection subcutaneously into the skin of a finger. The syringe appears prepared for injection with the needle aimed at the finger's surface, demonstrating technique for subcutaneous injection.*

FDA Label Image

Tocli-img-57.jpg (Tocil Img 57)

An instructional illustration demonstrating how to hold a syringe for subcutaneous injection. The image highlights proper finger placement on the syringe plunger and barrel, with a focus on the thumb pressing down to administer the injection.*

FDA Label Image

Tocli-img-58.jpg (Tocil Img 58)

An instructional illustration showing a hand holding a prefilled syringe, demonstrating the process of injection with an arrow indicating the direction of injection. A close-up inset highlights the syringes' label area. The image is labeled as Figure T.*

FDA Label Image

Tocli-img-59.jpg (Tocil Img 59)

An instructional diagram panel labeled Step 7 instructing the user to throw away the used prefilled syringe. The panel features an orange arrow pointing right on the left, and a purple gradient background on the right containing the disposal instruction text.*

FDA Label Image

Tocli-img-60.jpg (Tocil Img 60)

An instructional illustration showing a hand holding a pre-filled syringe with the needle cap removed, positioned above a sharps disposal container labeled "Sharps Disposal." A purple downward arrow indicates the syringe should be disposed of into the container.*

FDA Label Image

Tocli-img-61.jpg (Tocil Img 61)

An instructional graphic panel labeled as Step 8, titled "Record your injection," using a purple and orange color scheme to guide users through the injection process.*

FDA Label Image

Tocli-img-62.jpg (Tocil Img 62)

An instructional illustration showing a hand holding a pencil poised over a blank sheet of paper, suggesting an action related to writing or drawing.*

FDA Label Image

Tocli-img-63.jpg (Tocil Img 63)

An instructional illustration labeled Figure K showing a person washing hands under a running faucet with soap and water, with bubbles visible around the hands.*

FDA Label Image

Tocli-label-01.jpg (Tocil Label 01)

Label for TYENNE (tocilizumab-aazg) injection, solution, 162 mg/0.9 mL for subcutaneous use. The label indicates it is a prescription drug from Fresenius Kabi USA, LLC, with space for lot and expiration dates. Includes an NDC barcode and U.S. license number 2146.*

FDA Label Image

Tocil-label-02.jpg (Tocil Label 02)

Packaging label for TYENNE 162 mg/0.9 mL injection, a subcutaneous solution containing Tocilizumab-aazg. The label specifies a single-dose prefilled syringe with instructions to discard unused portions. Manufactured by Fresenius Kabi USA, LLC, the label includes dosage form, strength, contents, and storage information, along with tamper-evident peel-off strips and a barcode.*

FDA Label Image

Tocil-label-03.jpg (Tocil Label 03)

Label for TYENNE (tocilizumab-aazg) injection, solution, 162 mg/0.9 mL for subcutaneous use. The label displays the proprietary and generic names, dosage strength, administration route, and manufacturer Fresenius Kabi USA, LLC. It also includes a barcode, QR code, and spaces for lot number and expiration date.*

FDA Label Image

Tocil-label-04.jpg (Tocil Label 04)

Packaging label for TYENNE 162 mg/0.9 mL injection, solution for subcutaneous use. The label includes the product name, active ingredient Tocilizumab-aazg, and highlights that it contains 1 single-dose autoinjector. It is labeled for prescription use only and manufactured by Fresenius Kabi USA, LLC. The label also provides storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.